最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13科美诊断27.6322.441.9928.52亿行业平均 48.8947.044.50104.32亿行业中值35.7936.752.3948.75亿1英科医疗9.6210.370.86152.00亿2九安医疗 10.0410.150.79169.41亿3新华医疗14.1313.101.1590.58亿4康德莱14.8414.851.2331.97亿5奥美医疗 14.8814.581.5353.76亿6振德医疗15.2814.400.9755.48亿7山东药玻15.5515.601.79147.12亿8维力医疗 15.7216.341.8435.85亿9奥泰生物15.9216.791.2950.77亿10九强生物16.1114.981.9779.78亿11安杰思 17.0117.212.0650.50亿12三鑫医疗18.1218.132.9841.22亿 截至2025年一季报，共有9家机构持 ...

证券研究报告 | 公司深度 gszqdatemark 2025 06 19 年 月 日 海澜之家（600398.SH） 男装赛道佼佼者，业务突围打造零售平台 公司是大众服饰品牌龙头之一，男装主业规模稳健、优势突出，品牌零售管理新 业务（京东奥莱+FCC）未来增速较快、成长空间广阔。我们在本篇报告中梳理过 去公司基本面变化及核心竞争力，并对未来盈利表现及业务趋势做出判断： 男装主业稳扎稳打，产品积极求变，牢占龙头位置。1）主品牌：定位于大众男装， 产品兼具品质与性价比。过去几年内男装行业竞争格局有所优化，公司凭借类直 营的管理模式，在 2014~2019 年以较快的速度完成了品牌及渠道规模的扩张， 2024 年末主品牌线下门店已达近 6000 家，未来门店质量+电商利润率稳步提升 有望带动主品牌业绩稳健成长。我们综合估计 2025~2027 年 HLA 品牌收入分别 158.0/161.2/165.3 亿元，同比分别 +3%/+2%/+3% ，毛利率预 计分别为 47.5%/47.8%/48.1%。2）团购系列：公司合作优质大客户并积极主动获取订单， 我们估计 2025~2027 年团购定制系列收入分别为 24 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：600398 公司简称：海澜之家 海澜之家集团股份有限公司2024年年度报告摘要 第一节 重要提示 1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到www.sse.com.cn网站仔细阅读年度报告全文。 2、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3、公司全体董事出席董事会会议。 4、天衡会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 5、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司拟以2024年度利润分配实施股权登记日的股本为基数，向全体股东每10股派发现金股利人民币1.80 元（含税），剩余未分配利润结转至下一年度，本年度不进行资本公积金转增股本。截至2024年12月31 日，公司总股本为4,802,770,296股，以此计算合计拟派发现金红利864,498,653.28元（含税）。公司2024 年半年度已向全体股东派发现金红利1,104 ...

Core Viewpoint - The company reported its Q1 2025 financial results, showing a revenue increase but a decline in net profit due to increased R&D investments. Financial Performance - In Q1 2025, the company achieved revenue of 1.274 billion yuan, a year-on-year increase of 20.41% [1] - The net profit attributable to shareholders was 65 million yuan, a year-on-year decrease of 11.44% [1] - The net profit excluding non-recurring items was 66 million yuan, a year-on-year decrease of 8.97% [1] - The gross margin for Q1 2025 was 17.49%, an increase of 0.70 percentage points year-on-year [3] Expense Management - The company's expense ratio for Q1 2025 was 11.60%, an increase of 1.40 percentage points year-on-year [4] - Breakdown of expense ratios: sales (1.96%), management (5.50%), R&D (4.95%), and financial expenses (-0.81%) with respective year-on-year changes of 0.14, -1.27, +0.42, and +2.12 percentage points [4] R&D and Market Expansion - The company is enhancing its R&D capabilities, solving key material challenges and achieving breakthroughs in high-end product technologies [5] - Significant advancements include the development of high-temperature, high-voltage ceramic powder for MLCCs and the domestic replacement of precious metal electrode paste [5] - The company is targeting emerging markets, with projected revenue growth in automotive electronics (+66%), communications (+24%), and industrial control (+16%) for 2024 [5] Investment Outlook - The company maintains its profit forecasts for 2025-2027, expecting revenues of 5.734 billion, 6.523 billion, and 7.295 billion yuan, representing year-on-year growth of 16.1%, 13.8%, and 11.8% respectively [6] - Projected net profits for the same period are 505 million, 711 million, and 920 million yuan, with year-on-year growth of 49.7%, 40.7%, and 29.4% respectively [6] - The expected EPS for 2025-2027 is 0.44, 0.61, and 0.79 yuan, with a current stock price of 13.48 yuan corresponding to PE ratios of 30.88x, 21.95x, and 16.96x [6]